MannKind Acquires scPharmaceuticals, Boosting Revenue Growth and Leadership in Cardiometabolic and Lung Diseases

MannKind to acquire scPharmaceuticals for $5.35 per share, with a potential total consideration of up to $6.35 per share. The deal aims to accelerate revenue growth and strengthen MannKind's position in cardiometabolic and lung diseases. scPharmaceuticals markets FUROSCIX, a treatment for edema due to chronic heart failure and chronic kidney disease, with estimated total addressable market opportunity of over $10 billion in the US. The acquisition is expected to diversify and accelerate double-digit revenue growth.